

Parameter	Acceptable	Optimal
Indication	Adults at risk of invasive <i>S. aureus</i> infections or pregnant women	Adults at risk of invasive <i>S. aureus</i> infections and <i>S. aureus</i> SSTI/pneumonia/UTI
Target Demographic	>65 yoa, pregnant women*	All ages
Presentation	Single-dose vial, liquid	Single-dose vial, lyophilized
Dose Regimen	Two doses IV, one week apart	One dose IV
Human Dose	TBD	TBD, predictable PK
Safety Profile	Limited local side effects, limited antidrug antibody response	No local side effects, no antidrug antibody response
Efficacy	>90%	>95%
Durability of Protection	One month, incl neonatal sepsis	One year
Coverage	>80% of globally clinically relevant <i>S. aureus</i> isolates including >90% drug-resistant strains	>90% of globally clinically relevant <i>S. aureus</i> isolates including >99% of drug-resistant strains
Stability	18 months at 2-8°C	Three years at 2-8°C
Contraindications	-	-
Marketing Attributes	COG acceptable in LMIC	COG acceptable in LMIC

*Maternal immunization to protect against neonatal sepsis